Taiwan RUO Immunoassay Market Size, Share, Opportunities, And Trends By Product Type (Immunoassay Kits, Immunoassay Reagents, Microplate Reader, Microplates, Analyzers (Automated Analyzers, Non-Automated Analyzers), Microplate Washers, Others), By Sample Type (Plasma, Blood Serum, Urine, Saliva, Cell or Tissue Culture Medium, Others), By Application (Oncology, Blood Screening and Toxicology, Infectious Disease, Cardiology, Allergy Diagnostic, Rare and Emerging Condition Diagnostic, Others), And By End-User (Research and Academic Laboratories, Pharmaceutical and Biotechnology Companies) - Forecasts From 2025 To 2030

Taiwan RUO Immunoassay Market Size:

Taiwan RUO immunoassay market is expected to grow at a CAGR of 11.88% from 2025 to 2030.

Taiwan is an aging society, and the elderly population (aged over 65) has doubled in the last 10 years, turning into an aged society, and the percentage is expected to surpass 20% by 2025. In response, the government offers various strategic programs for this age group as it is more prone to different types of diseases. The rise in chronic ailments such as cancer and diabetes are on the rise. The number of people with diabetes for the age group (20-79 y) was estimated at 2,457.2 (in 1,000s) in 2021, 2,979.4 in 2030, and 3,030.7 in 2045. The cancer incidence was 121,762 in 2021, with 51,656 mortalities.

As the technology continues to develop, RUO immunoassays are likely to become an even more valuable tool for healthcare providers in Taiwan. Firstep Bioresearch, Inc. is a leading manufacturer of Diagnostic Instruments and Test Kits. The company has emerged as a prominent provider of contract manufacturing services (OEM/ODM) for in vitro diagnostic products. It specializes in producing high-quality reagents and medical devices using the Lateral Flow Immunochromatographic Technique and develops a range of Antigen and Antibody Rapid Tests. It is committed to advancing innovative technologies through collaborations with renowned engineering universities. 

The grant amounts to KRW General Biologicals Corporation (GBC) is the first company to develop the first In-vitro Diagnostic (IVD) HBV kit using RIA-based technology as part of Taiwan's nationwide Liver Disease Prevention Program, and has a range of offerings from RIA, ELISA (Immunoassay), and Real-Time PCR (Molecular) to CTC (Circulating Tumor Cell). With an expanding range of products including Tumor markers, Fertility, Torch, and Thyroid tests, GBC now has two R&D Centers (Hsin Chu, Taiwan, and San Diego, USA). 

In July 2023, the company unveiled two CellBio™ circulating tumor cell (CTC) cancer detection products. These CTC detection systems are viewed globally at the forefront of science and are used for early detection, treatment validation, and therapy monitoring with rapid, accessible, and affordable diagnostic solutions. Its GB SARS-CoV-2 Ab is a semi-quantitative ELISA kit designed to detect antibodies against the SARS-CoV-2 virus (anti-SARS-CoV-2) in human serum or plasma.   

Several major companies are developing innovative products and collaborating with universities and other research institutions. For example, in August 2023, Elixiron collaborated with Yang-Ming University to co-develop innovative immunotherapy technology for head and neck cancer, which involves a novel drug that combines a tumor macrophage-targeting antibody with an interleukin-10 fusion protein. Multi-Plex Immunoassay (MPI) offered by the Institute of Biomedical Sciences, Academia Sinica is a technology for simultaneous quantification of analytes in serum/plasma and culture supernatants, serving as a valuable tool in disease mechanistic studies and biomarker discovery. It provides cytokine and chemokine analysis in the field of immunology using fully validated detection panels.

Taiwan RUO Immunoassay Market Segmentation

By Product Type

• Immunoassay Kits
  • Enzyme-Linked Immunosorbent Assay (ELISA) Kits
    • Conventional
    • Manual
  • Radioimmunoassay (RIA Kits)
    • Conventional
    • Manual
  • Chemiluminescent Immunoassay (CLIA) Kits
• Immunoassay Reagents
• Microplate Reader
• Microplates
• Analyzers
  • Automated Analyzers
  • Non-Automated Analyzers
• Microplate Washers
• Others

By Sample Type

• Plasma
• Blood Serum
• Urine
• Saliva
• Cell or Tissue Culture Medium
• Others

By Application

• Oncology
• Blood Screening and Toxicology
• Infectious Disease
• Cardiology
• Allergy Diagnostic
• Rare and Emerging Condition Diagnostic
• Others

By End-User

• Research and Academic Laboratories
• Pharmaceutical and Biotechnology Companies

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

4.1. Product Pipeline

5. TAIWAN RUO IMMUNOASSAY MARKET BY PRODUCT TYPE

5.1. Introduction

5.2. Immunoassay Kits

5.2.1. Enzyme-Linked Immunosorbent Assay (ELISA) Kits

5.2.1.1. Conventional 

5.2.1.2. Manual

5.2.2. Radioimmunoassay (RIA Kits)

5.2.2.1. Conventional 

5.2.2.2. Manual

5.2.3. Chemiluminescent Immunoassay (CLIA) Kits

5.3. Immunoassay Reagents

5.4. Microplate Reader

5.5. Microplates

5.6. Analyzers

5.6.1. Automated Analyzers

5.6.2. Non-Automated Analyzers

5.7. Microplate Washers

5.8. Others

6. TAIWAN RUO IMMUNOASSAY MARKET BY SAMPLE TYPE

6.1. Introduction

6.2. Plasma 

6.3. Blood Serum

6.4. Urine

6.5. Saliva

6.6. Cell or Tissue Culture Medium

6.7. Others

7. TAIWAN RUO IMMUNOASSAY MARKET BY APPLICATION

7.1. Introduction

7.2. Oncology

7.3. Blood Screening and Toxicology

7.4. Infectious Disease

7.5. Cardiology

7.6. Allergy Diagnostic

7.7. Rare and Emerging Condition Diagnostic

7.8. Others

8. TAIWAN RUO IMMUNOASSAY MARKET BY END-USER

8.1. Introduction

8.2. Research and Academic Laboratories

8.3. Pharmaceutical and Biotechnology Companies

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. F. Hoffmann-La Roche Ltd

10.2. Merck KGaA

10.3. Quanterix Corporation

10.4. Thermo Fisher Scientific Inc. 

10.5. Becton Dickinson

10.6. Seegene Inc.

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

F. Hoffmann-La Roche Ltd

Merck KGaA

Quanterix Corporation

Thermo Fisher Scientific Inc. 

Becton Dickinson

Seegene Inc.